The neurovascular unit (NVU) comprises brain endothelial cells, pericytes or vascular
smooth muscle cells, glia and neurons. The NVU controls blood–brain barrier (BBB) …

Cerebral amyloid angiopathy (CAA) results from deposition of β‐amyloid in the media and
adventitia of small arteries and capillaries of the leptomeninges and cerebral cortex and is a …

Amyloid-β peptide (Aβ) interacts with the vasculature to influence Aβ levels in the brain and
cerebral blood flow, providing a means of amplifying the Aβ-induced cellular stress …

Elimination of amyloid-β peptide (Aβ) from the brain is poorly understood. After intracerebral
microinjections in young mice, 125I-Aβ1-40 was rapidly removed from the brain (t 1/2≤ 25 …

Active immunization with the amyloid β (Aβ) peptide has been shown to decrease brain Aβ
deposition in transgenic mouse models of Alzheimer's disease and certain peripherally …

The main receptors for amyloid-beta peptide (Aβ) transport across the blood-brain barrier
(BBB) from brain to blood and blood to brain are low-density lipoprotein receptor related …

The blood–brain barrier (BBB) plays critical roles in the maintenance of central nervous
system (CNS) homeostasis. Dysfunction of the BBB occurs in a number of CNS diseases …

Amyloid β-peptide (Aβ) clearance from the central nervous system (CNS) maintains its low
levels in brain. In Alzheimer's disease, Aβ accumulates in brain possibly because of its faulty …

Certain disease states are characterized by disturbances in production, accumulation or
clearance of protein. In Alzheimer disease, accumulation of amyloid-β (Aβ) in the brain and …

Amyloid β protein (AβP) is the major constituent of senile plaques associated with
Alzheimer's disease (AD). However, its mechanistic role in AD pathogenesis is poorly …